SynthesisCancer medicine2021

Progression-free survival assessed per immune-related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune-checkpoint inhibitors in lung cancer: A systematic review and meta-analysis.

Guang-Li Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.